Bristol-Myers Squibb Co (BMY) : Fort Washington Investment Advisors Inc Oh scooped up 1,350,472 additional shares in Bristol-Myers Squibb Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 1,455,655 shares of Bristol-Myers Squibb Co which is valued at $82,331,847.Bristol-Myers Squibb Co makes up approximately 1.51% of Fort Washington Investment Advisors Inc Oh’s portfolio.
Other Hedge Funds, Including , Northwestern Mutual Investment Services sold out all of its stake in BMY during the most recent quarter. The investment firm sold 1 shares of BMY which is valued $57. Trexquant Investment Lp added BMY to its portfolio by purchasing 20,300 company shares during the most recent quarter which is valued at $1,150,198. Bristol-Myers Squibb Co makes up approx 0.26% of Trexquant Investment Lp’s portfolio.Spc Financial boosted its stake in BMY in the latest quarter, The investment management firm added 7,400 additional shares and now holds a total of 26,374 shares of Bristol-Myers Squibb Co which is valued at $1,328,195. Bristol-Myers Squibb Co makes up approx 0.44% of Spc Financial’s portfolio.
Bristol-Myers Squibb Co opened for trading at $56.58 and hit $56.84 on the upside on Monday, eventually ending the session at $56.76, with a gain of 0.14% or 0.08 points. The heightened volatility saw the trading volume jump to 73,87,424 shares. Company has a market cap of $94,859 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.77 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $0.65. The company had revenue of $4922.00 million for the quarter, compared to analysts expectations of $4796.98 million. The company’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Shares were Reiterated by Deutsche Bank on Oct 28, 2016 to “Hold” and Lowered the Price Target to $ 52 from a previous price target of $59 .Shares were Reiterated by Barclays on Sep 9, 2016 to “Equal Weight” and Lowered the Price Target to $ 65 from a previous price target of $75 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.